{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T19:49:35Z","timestamp":1769197775184,"version":"3.49.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1016\/j.rmed.2011.09.002","type":"journal-article","created":{"date-parts":[[2011,10,31]],"date-time":"2011-10-31T10:52:59Z","timestamp":1320058379000},"page":"91-101","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"title":["Benefits of adding fluticasone propionate\/salmeterol to tiotropium in moderate to severe COPD"],"prefix":"10.1016","volume":"106","author":[{"given":"Nicola A.","family":"Hanania","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glenn D.","family":"Crater","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea N.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda H.","family":"Emmett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dianne M.","family":"O\u2019Dell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis E.","family":"Niewoehner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5 Suppl A","key":"10.1016\/j.rmed.2011.09.002_bib1","first-page":"S14","article-title":"Contemporary issues in the care of patients with chronic obstructive pulmonary disease","volume":"11","author":"Urbano","year":"2005","journal-title":"J Manag Care Pharm"},{"issue":"7","key":"10.1016\/j.rmed.2011.09.002_bib2","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1513\/pats.200701-001FM","article-title":"The epidemiology and economics of chronic obstructive pulmonary disease","volume":"4","author":"Mannino","year":"2007","journal-title":"Proc Am Thorac Soc"},{"issue":"9","key":"10.1016\/j.rmed.2011.09.002_bib3","doi-asserted-by":"crossref","first-page":"639","DOI":"10.7326\/0003-4819-147-9-200711060-00009","article-title":"Management of stable chronic obstructive pulmonary disease: a systematic review for a clinical practice guideline","volume":"147","author":"Wilt","year":"2007","journal-title":"Ann Intern Med"},{"issue":"8","key":"10.1016\/j.rmed.2011.09.002_bib4","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.rmed.2008.04.019","article-title":"Effect of fluticasone propionate\/salmeterol (250\/50 microg) or salmeterol (50 microg) on COPD exacerbations","volume":"102","author":"Ferguson","year":"2008","journal-title":"Respir Med"},{"issue":"8","key":"10.1016\/j.rmed.2011.09.002_bib5","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJMoa063070","article-title":"Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease","volume":"356","author":"Calverley","year":"2007","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.rmed.2011.09.002_bib6","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1183\/09031936.03.00027003","article-title":"Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease","volume":"22","author":"Calverley","year":"2003","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.rmed.2011.09.002_bib7","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1183\/09031936.03.00031402","article-title":"Efficacy and safety of budesonide\/formoterol in the management of chronic obstructive pulmonary disease","volume":"21","author":"Szafranski","year":"2003","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmed.2011.09.002_bib8","first-page":"CD007891","article-title":"Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease","volume":"5","author":"Welsh","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.rmed.2011.09.002_bib9","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.pupt.2006.06.001","article-title":"A pilot study to assess the effects of combining fluticasone propionate\/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD","volume":"20","author":"Cazzola","year":"2007","journal-title":"Pulm Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.rmed.2011.09.002_bib10","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1136\/thx.2007.087213","article-title":"Superiority of \"triple\" therapy with salmeterol\/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD","volume":"63","author":"Singh","year":"2008","journal-title":"Thorax"},{"issue":"8","key":"10.1016\/j.rmed.2011.09.002_bib11","doi-asserted-by":"crossref","first-page":"545","DOI":"10.7326\/0003-4819-146-8-200704170-00152","article-title":"Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial","volume":"146","author":"Aaron","year":"2007","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1016\/j.rmed.2011.09.002_bib12","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1136\/thx.54.7.581","article-title":"Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease","volume":"54","author":"Bestall","year":"1999","journal-title":"Thorax"},{"issue":"6","key":"10.1016\/j.rmed.2011.09.002_bib13","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1183\/09031936.04.00014304","article-title":"Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS\/ERS position paper","volume":"23","author":"Celli","year":"2004","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.rmed.2011.09.002_bib14","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1164\/ajrccm.159.1.9712108","article-title":"Spirometric reference values from a sample of the general U.S. population","volume":"159","author":"Hankinson","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.rmed.2011.09.002_bib15","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1081\/COPD-200050651","article-title":"Measurement properties and interpretability of the Chronic respiratory disease questionnaire (CRQ)","volume":"2","author":"Sch\u00fcnemann","year":"2005","journal-title":"COPD"},{"issue":"3","key":"10.1016\/j.rmed.2011.09.002_bib16","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1017\/S0033291700035558","article-title":"The Inventory of Depressive Symptomatology (IDS): psychometric properties","volume":"26","author":"Rush","year":"1996","journal-title":"Psychol Med"},{"issue":"6","key":"10.1016\/j.rmed.2011.09.002_bib17","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","article-title":"The hospital anxiety and depression scale","volume":"67","author":"Zigmond","year":"1983","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.rmed.2011.09.002_bib18","series-title":"GOLD - the global initiative for chronic obstructive lung disease","year":"2009"},{"issue":"2","key":"10.1016\/j.rmed.2011.09.002_bib19","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1183\/09031936.02.00269802","article-title":"A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease","volume":"19","author":"Casaburi","year":"2002","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.rmed.2011.09.002_bib20","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/15412550902724073","article-title":"Formoterol and tiotropium compared with tiotropium alone for treatment of COPD","volume":"6","author":"Tashkin","year":"2009","journal-title":"COPD"},{"issue":"5","key":"10.1016\/j.rmed.2011.09.002_bib21","doi-asserted-by":"crossref","first-page":"317","DOI":"10.7326\/0003-4819-143-5-200509060-00007","article-title":"Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial","volume":"143","author":"Niewoehner","year":"2005","journal-title":"Ann Intern Med"},{"issue":"8","key":"10.1016\/j.rmed.2011.09.002_bib22","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1164\/rccm.2112055","article-title":"Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease","volume":"166","author":"Mahler","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.rmed.2011.09.002_bib23","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1378\/chest.124.3.834","article-title":"The efficacy and safety of fluticasone propionate (250 microg)\/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD","volume":"124","author":"Hanania","year":"2003","journal-title":"Chest"},{"issue":"9356","key":"10.1016\/j.rmed.2011.09.002_bib24","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(03)12459-2","article-title":"Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial","volume":"361","author":"Calverley","year":"2003","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.rmed.2011.09.002_bib25","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1183\/09031936.05.00140404","article-title":"Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD","volume":"26","author":"van Noord","year":"2005","journal-title":"Eur Respir J"},{"issue":"7","key":"10.1016\/j.rmed.2011.09.002_bib26","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.rmed.2010.02.017","article-title":"Combining tiotropium and salmeterol in COPD: effects on airflow obstruction and symptoms","volume":"104","author":"van Noord","year":"2010","journal-title":"Respir Med"},{"issue":"2","key":"10.1016\/j.rmed.2011.09.002_bib27","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1378\/chest.07-2138","article-title":"Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD","volume":"134","author":"Rabe","year":"2008","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.rmed.2011.09.002_bib28","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1183\/09031936.00115308","article-title":"Anti-inflammatory effects of salmeterol\/fluticasone, tiotropium\/fluticasone or tiotropium in COPD","volume":"33","author":"Perng","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmed.2011.09.002_bib29","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1164\/rccm.200904-0492OC","article-title":"Efficacy and tolerability of budesonide\/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease","volume":"180","author":"Welte","year":"2009","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611111003258?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611111003258?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T11:16:08Z","timestamp":1760613368000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611111003258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["S0954611111003258"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2011.09.002","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Benefits of adding fluticasone propionate\/salmeterol to tiotropium in moderate to severe COPD","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2011.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}